Business Wire · VRDN · November 9, 2026

Viridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing

Get the app for more

Explore stock news, insights and company research.